Evidence map›Paper›PMID 30909401›Full record

ReviewNanomaterials (Basel, Switzerland)2019

Application of Solid Lipid Nanoparticles to Improve the Efficiency of Anticancer Drugs.

Laura Bayón-Cordero, Itziar Alkorta, Lide Arana

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers.

0numbers the graph read from it
0cells of the map it votes in
123citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

123 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Nanosystems for delivery of indolicidin peptide.Frontiers in medical technology · 2026
    Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Inhalable nanoparticle-based drug delivery system for non-small cell lung cancer therapy: promises and challenges.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025
    Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Functionalized Nanomaterials in Cancer Treatment: A Review.International journal of molecular sciences · 2025
    Review
  19. Article
  20. Article

63 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Laura Bayón-CorderoBiochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), Barrio Sarriena S/N, 48940 Leioa, Spain. lbayon95@gmail.com.
Itziar AlkortaBiochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), Barrio Sarriena S/N, 48940 Leioa, Spain. itzi.alkorta@ehu.eus.
Lide AranaBiochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), Barrio Sarriena S/N, 48940 Leioa, Spain. lide.arana@ehu.eus.ORCID 0000-0002-5832-1339

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug delivery systems have opened new avenues to improve the therapeutic effects of already-efficient molecules. Particularly, Solid Lipid Nanoparticles (SLNs) have emerged as promising nanocarriers in cancer therapy. SLNs offer remarkable advantages such as low toxicity, high bioavailability of drugs, versatility of incorporation of hydrophilic and lipophilic drugs, and feasibility of large-scale production. Their molecular structure is crucial to obtain high quality SLN preparations and it is determined by the relationship between the composition and preparation method. Additionally, SLNs allow overcoming several physiological barriers that hinder drug delivery to tumors and are also able to escape multidrug resistance mechanisms, characteristic of cancer cells. Focusing on cell delivery, SLNs can improve drug delivery to target cells by different mechanisms, such as passive mechanisms that take advantage of the tumor microenvironment, active mechanisms by surface modification of SLNs, and codelivery mechanisms. SLNs can incorporate many different drugs and have proven to be effective in different types of tumors (i.e., breast, lung, colon, liver, and brain), corroborating their potential. Finally, it has to be taken into account that there are still some challenges to face in the application of SLNs in anticancer treatments but their possibilities seem to be high.

Indexed as

cancerchemotherapydrug deliverysolid lipid nanoparticlestumor

Identifiers

PMID30909401
PMCPMC6474076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.